Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00397293
Status:
COMPLETED
Last Update Posted:
2010-08-24
First Post:
2006-11-07
Brief Title:
Study of AT-101 in Combination With Topotecan in RelapsedRefractory Small Cell Lung Cancer
Sponsor:
Ascenta Therapeutics
Organization:
Ascenta Therapeutics
Study Overview
Official Title:
An Open-label Multicenter Phase III Study of AT-101 in Combination With Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer After Prior Platinum Containing First Line Chemotherapy
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label multicenter Phase III study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsedrefractory small cell lung cancer
Detailed Description:
Further Study Details provided by Ascenta
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None